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Abstract
Background:  Interferons are a group of proteins that trigger multiple responses including
prevention of viral replication, inhibition of cell growth, and modulation of cell differentiation. In
different mammary carcinoma cell lines IFNγ induces growth arrest at mid-G1. At the present there
are no in vivo studies in human breast. The aim of this study was to investigate the expression
patterns of IFNγ and its two receptors (IFNγ-Rα and IFNγ-Rβ) by Western blot and
immunohistochemistry, in order to elucidate its role in the different types of human breast cancer
(in situ and infiltrative).
Methods: Immunohistochemical and semiquantitative study of IFNγ, its receptors types (IFNγ-Rα
and IFNγ-Rβ), cell proliferation (proliferating cell nuclear antigen, also named PCNA), and
apoptosis (TUNEL method) was carried between the three breast groups (fibrocystic lesions, in
situ tumors and infiltrating tumors).
Results: In the three groups of patients, IFNγ and IFNγ-Rα immunoreactions appeared in the
cytoplasm while IFNγ-Rβ also was found in the nucleus. The optical density to IFNγ was higher in
in situ carcinoma than in benign and infiltrating tumors. When we observed IFNγ-Rα, the optical
density was lower in infiltrating carcinoma than in benign and in situ tumors (the higher density). To
IFNγ-Rβ, the optical density was similar in the three group samples. In tumor samples PCNA and
TUNEL index was significantly higher; than in benign diseases. PCNA index increased with the
malignance. No significant differences were found between cancer types to TUNEL. IFNγ could be
a potential therapeutic tool in breast cancer. However, tumor cells are able to escape from the
control of this cytokine in the early tumor stages; this is probably due to a decreased expression
of IFNγ, or also to an alteration of either its receptors or some transduction elements.
Conclusion: We conclude that the decrease in the % positive samples that expressed IFNγ and
IFNγ-Rα together with the nuclear localization of IFNγ-Rβ, could be a tumoral cell response,
although perhaps insufficient to inhibit the uncontrolled cell proliferation. Perhaps, IFNγ might be
unable to activate p21 to stop the cell cycle, suggesting a possible participation in breast cancer
development.
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Background
Interferons belong to a protein family involved in viral
replication prevention, cell growth inhibition and cell dif-
ferentiation modulation [1]. IFNγ was described as a 17
kDa peptide that is secreted by antigen activated lym-
phocytes and natural killer cells. Also, it has been reported
that IFNγ has antiviral activity, inhibits cell growth and
modulates cell differentiation [2]. IFNγ acts throughout a
specific membrane receptor, which is composed by two
different subunits: IFNγ-Rα and IFNγ-Rβ [3]. IFNγ-Rα is
sufficient for ligand binding but it is necessary the pres-
ence of Rβ to begin the IFNγ signal transduction [4]. IFNγ
receptor complex has been described in a number of dif-
ferent tissues as endothelial cells, fibroblasts, neuronal
cells, melanocytes and prostate cells [5,6].
In addition to its role in immune cells, IFNγ inhibits the
growth of a number of nonhematopoietic cell types,
including several tumor types. In fact, it has been consid-
ered as an antitumor agent [7-9].
The IFNγ ability to inhibit the growth of several tumor cell
lines, including breast cancer cells, has been demon-
strated in different studies [10-12]. This effect requires the
signal transduction through the IFNγ receptor, so the
tumor proliferation rate was higher in animal cells that
expressed lower number of functional receptors [13,14].
In breast cancer patients with skin metastasis, local injec-
tion of IFNγ results in the total or partial regression of the
skin lesions [15]. Other authors have been showed that
IFNγ increases the growth inhibitory effect of tamoxifen in
breast metastatic carcinomas [16,17]. In this way, it has
been show that IFNγ produce this antitumoral effect up-
regulating the expression of p21 and resulting cell cycle
arrest in breast cancer cell lines [18].
At present and in our knowledge, there are no studies of
IFNγ and its receptors expression reported by immunohis-
tochemistry and western blot, in different non malignant
and carcinomatous human breast tissue. The aim of this
study was to elucidate the expression patterns of IFNγ and
its receptors in human benign breast lesions and in in situ
and infiltrating breast cancers, and to relate to the prolif-
eration and apoptosis levels found in this tissues.
Methods
Patients and histological samples
Total or partial mastectomy specimens obtained from 52
women, who were clinically and histopathologically diag-
nosed of breast adenocarcinoma during 1998 in our hos-
pital, were used for the study. Seventeen of these women
(aged from 37 to 75 years; mean: 52.8) presented in situ
carcinoma; one of these 17 women also showed lymph
node infiltration at the time of surgery. Thirty-five women
(aged from 40 to 82 years; mean: 59.94) had infiltrating
carcinoma; 13 of these 35 women showed lymph node
infiltration at the time of surgery, and 7 of these 13 devel-
oped metastasis 7–24 months after surgery. At present
(January 2005), neither the remaining 22 women with
infiltrating tumors nor the 17 women with in situ tumors
have developed metastasis.
Tumor samples were compared with breast biopsies from
13 women (aged from 16 to 59 years; mean: 43.8) with
benign lesions including ductal and lobular hyperplasia,
fibroadenoma and fibrocystic changes. We always use the
normal regions into these biopsies. All infiltrative tumor
samples were classified by the TNM system (UICC, 1968).
Each sample was divided into two portions: one that was
immediately processed for immunohistochemistry and
the other were frozen in liquid nitrogen and maintained
at -80°C for Western blot analysis. Removal of tissues was
made by a Gynaecological Specialist MD and the samples
were diagnosed by a Pathological Specialist MD (Ruiz A.).
All pathological, clinical or personal data were ano-
nymized and separated from any personal identifiers. This
study was made with the consent of the written patients'
relatives or their family in autopsy cases. All the proce-
dures followed were examined and approved by the Princ-
ipe de Asturias Hospital Ethics Committee and were in
accordance with the ethical standards of the responsible
committee on human experimentation, with the Helsinki
Declaration of 1975 (revised in 1983) and the Committee
on Publication Ethics (COPE) guidelines.
Antibodies
The primary antibodies used were: mouse anti-human
PCNA; goat anti-human IFNγ; and rabbit anti-human
IFNγ-Rα and IFNγ-Rβ (Santa Cruz Biotechnology, Califor-
nia, Ca, USA). In Western blot analysis mouse anti-
chicken α-actin (Amersham, Madrid, Spain) was also used
to examine the relative expression of the other proteins.
Western blot analysis
For Western blot analysis, tissues were homogenized in
the extraction buffer (0.005 M Tris-HCl, pH 8) with addi-
tion of a cocktail of protease inhibitors (10 mM iodoa-
cetamide, 100 mM phenylmethyl sulphonic fluoride,
0.01 mg/ml of soybean trypsin inhibitor and 1 μl/ml of
leupeptin) and phosphates inhibitors (10 mM sodium
fluoride and 1 mM sodium orthovanadate) in the pres-
ence of 0.5% Triton X-100. Homogenates were centrifu-
gated for 10 min at 10,000 rpm. The protein
concentration of supernatants was calculated by the Brad-
ford method. Then, supernatants were equilibrated with
loading buffer (10% SDS in Tris/HCl pH 8 containing
50% glycerol, 0.1 mM 2-beta-mercaptoethanol and 0.1%
bromophenol blue) at 50 μg/ml. The mixture was dena-BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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tured for 5 min at 100°C, and aliquots of 10 μl of
homogenate were separated in SDS-polyacrylamide slab
minigels (15% gels).
Separated proteins were transferred in the transfer buffer
(25 mM Tris-HCl, 192 mM glycine, 0.1% SDS and 20%
methanol). Nitrocellulose membranes (0.2 μm), were
blocked for 1 h with 1% donkey serum in TBS, and incu-
bated overnight at room temperature with the primary
antibodies at 1:150 (IFNγ and IFNγ-Rβ), 1:500 (IFNγ-Rα)
or 1:10000 (α-actin) in TBS with 5% bovine serum albu-
mine (BSA). After extensive washing with TBS/Tween-20
(TBST), the membranes were incubated with donkey anti-
goat (IFNγ) and swin anti-rabbit (IFNγ-Rα and IFNγ-Rβ)
or rabbit anti-mouse (α-actin) biotinylated immunoglob-
ulins (Dako, Barcelona, Spain) for 1 h at 1:2500 dilution
in TBS with 5% BSA; and then washed and incubated with
the avidin-biotin-peroxidase complex (Vector Laborato-
ries, Burlingame, CA) at 1:1000 dilution. Furthermore,
mouse anti-chicken α-actin (Amersham, Madrid, Spain)
was also used at the same dilution to examine the relative
expression of the other proteins. After an intensive wash,
the filters were developed with an enhanced chemilumi-
nescence (ECL) kit, following the procedure described by
the manufacturer (Amersham, Buckinghamshire, UK).
ELISA analysis
For ELISA procedure, the protein concentration of
homogenates was calculated by the Bradford method. The
different antigens were coated on 96 well multiplates
overnight at 4°C. The plates were washed with TBS con-
taining 0.05% Tween 20 and blocked with 1% BSA in TBS
for 1 h at room temperature, and incubated with the dif-
ferent antibodies (anti-IFN-γ, IFNγ-Rα, IFNγ-Rβ) for 3 h
also at room temperature. After a new wash, the biotin-
conjugated anti-rabbit or anti-goat immunoglobulins
(Dako) were added to each well, incubated for 1 h at
room temperature, and then washed and incubated with
the avidin-biotin-peroxidase complex (Vector). The inter-
actions were visualized with 0.05% 2,2 azino di-3-etilben-
ziatioazolina sulphonic acid (ABTS) (Sigma) in 100 mM
citrate buffer, and were measured (optical density at 405
nm) in a spectrophotometer (Multiskan Bichromatic,
Labsystems, Finland).
Immunohistochemical analysis (IHC)
Tissues were fixed for 24 h at room temperature in 0.1 M
phosphate-buffered 10% formaldehyde, dehydrated and
embedded in paraffin. Sections (5-μm thick) were proc-
essed following the avidin-biotin-peroxidase complex
(ABC) method. Following deparaffinization, sections
were hydrated, incubated for 30 min in 0.3% H2O2
diluted in methanol to reduce endogenous activity. To
retrieve the antigen, the sections were incubated with 0.1
M citrate buffer (pH 6) for 2 min in a conventional pres-
sure cooker. After rinsing in TBS buffer, the slides were
incubated with normal donkey serum at 10% in TBS for
30 min to prevent non-specific binding of the first anti-
body. Thereafter, the primary antibodies were applied at a
dilution of 1:25 (IFNγ and IFNγ-Rβ), 1:125 (IFNγ-Rα) or
1:500 (PCNA) in TBS at 37°C overnight. Afterwards, the
sections were washed twice in TBS and then incubated
with donkey anti-goat (IFNγ), mouse anti-rabbit (IFNγ-Rα
and IFNγ-Rβ) or rabbit anti-mouse (PCNA) biotinylated
immunoglobulins (Dako, Barcelona, Spain) at 1:500 in
TBS. After 1 h of incubation with secondary antibody, the
sections were incubated with a standard streptavidin-
biotin-complex (Vector Laboratories, Burlingame, CA,
USA) and developed with 3,3'-diaminobenzidine (DAB),
using the glucose oxidase-DAB-nickel intensification
method.
Immunochemical procedure specificity was checked using
negative and positive controls. For negative controls of
immunoreactions, tissues of each type were incubated
with preimmune serum at the same immunoglobulin
concentration used for each antibody (Santa Cruz Bio-
technology). As positive controls, histologic sections
(immunohistochemistry) of thymus samples were incu-
bated with the same antibodies.
Co-localization studies
Co-localization studies for IFNγ-IFNRα or IFNγ-IFNRβ
was carried out in the same sections of each group. The
procedure was similar than in simple immunostaining,
but sections were first labelled with goat anti-human IFNγ
and rabbit anti-human IFNγ-Rα or IFNγ-Rβ (Santa Cruz
Biotechnology). In a second step sections were incubated
for 1 h with donkey anti-goat (IFNγ) and mouse anti-rab-
bit (IFNγ-Rα and IFNγ-Rβ) biotilinated immunoglobulins
(DAKO). In a third step, IFNγ was revealed using the glu-
cose oxidase-DAB-nickel intensification method; and
IFNγ-Rα or IFNγ-Rβ was revealed using the AP-red sub-
strate (Zymed) After this, sections were mounted in Aqua-
tex (Merck & Co., Inc, Whitethouse Station, NJ, USA)
Tunel method
For histological evaluation of apoptosis, the sections were
processed by terminal deoxynucleotidyl tranferase-medi-
ated dUTP nick end-labeling (TUNEL) method, using a
TdT FragEL-DNA fragmentation detection kit (Calbio-
chem-Oncogene, Cambridge, MA, USA), following man-
ufacturer's instructions. Sections were further
permeabilized by incubation with proteinase K (20 μg/
ml) for 15 min, and then sections were exposed for 5 min
to 3% H2O2 for endogenous peroxidase inhibition and
incubated in terminal deoxynucleotidyl tranferase (TdT)
(0.25 U/μl) labeling reaction mix for 1.5 hours at 37°C,
washed in TBS, incubated with the avidin-biotin-peroxi-
dase complex (Vector), developed with DAB (Sigma) andBMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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intensified by the glucose-oxidase method. Positive and
negative controls were also performed, using the HeLa
cells slides provided for such purpose in the Calbiochem
kit and following manufacturer's instructions. For addi-
tional controls, sections of the three group samples were
processed either without TdT enzyme in the labelling reac-
tion mix, as negative controls, or pretreated with DNAse
(1 μg/m1) for generation of the positive control slides.
Quantitative analysis
A comparative histologic quantification of immunolabe-
ling among the different groups of breast samples (in situ
adenocarcinomas, infiltrating adenocarcinomas and
benign lesions) was performed for each of the four anti-
bodies. Of each sample (breast), six histologic sections
were selected at random. In each section, the staining
intensity (optic density) per unit surface area was meas-
ured with an automatic image analyzer (Motic Images
Advanced version 3.2, Motic China Group Co., China) in
5 light microscopic fields per section, using the ×20 objec-
tive. For each positively immunostained section, one neg-
ative control section (the following in a series of
consecutive sections) was also used, and the optic density
of this control section was taken away from that of the
stained section. Data are given as optic density per unit
surface area (1 μm).
Statistical methods
From the average values obtained for each breast, the
means ± SD for each breast group were calculated. The
Table 1: Comparison of immunostaining intensities in Western blot analysis.
IFNγ IFNγ-Rα IFNγ-Rβ Actin
Benign lesions 9.75 ± 3.1a 18.59 ± 2.1a 18.81 ± 3.2a 57 ± 4.1a
In situ carcinoma 20.25 ± 1.9b 21.1 ± 3.6a 19.68 ± 4.1a 49 ± 3.4a
Infiltrating carcinoma 13 ± 2.7a 13.51 ± 2.2b 22.01 ± 6.8a 54 ± 3.8a
Comparison of immunostaining intensities (measured as average optical density ± SD) in Western blot analysis of bening breast lesions, in situ and 
infiltrating breast cancer. The labeled cells are classified in three groups according to their intensity range: low (< 10), intermediate (between 10 and 
15) and high (>20). For each protein, values with different superscript letter differ significantly (P ≤ 0.05) between them. Those values sharing the 
same superscript are not statistically different from each other. Statistical analysis refers to each antibody separately. The mean values and SD for 
each group have been calculated from all samples corresponding to the group.
Western blot analysis of IFNγ, IFNγ-Rα, IFNγ-Rβ and α-actin after 15% polyacrilamide gel electrophoresis Figure 1
Western blot analysis of IFNγ, IFNγ-Rα, IFNγ-Rβ and α-actin after 15% polyacrilamide gel electrophoresis. BP, benign patholo-
gies. ISC, in situ carcinoma. IC, infiltandrating carcinoma. For each antibody used, a single band – at their corresponding molec-
ular weight – was found: IFNγ (17 kDa), IFNγ-Rα (80 kDa), IFNγ-Rβ (70 kDa) and α-actin (40 kDa).BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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number of sections examined was determined by succes-
sive approaches to obtain the minimum number required
to reach the lowest SD. The statistical significance between
means of the different breast group samples was assessed
by the Fisher exact or χ2 test at p ≤ 0.05, by multiple pair-
wise comparisons of all the values for each breast zone,
for each specific antibody separately.
Results
Western Blot analysis
For each antibody used, a single band – at their corre-
sponding molecular weight – was found: IFNγ (17 kDa),
IFNγ-Rα (80 kDa) and IFNγ-Rβ (70 kDa). The immunore-
action appeared in the three lesion groups (Fig. 1). Com-
parison of optical density band's revealed significant
differences (p ≤ 0.05) between three breast groups: the
highest optical density was found in in situ carcinomas
(IFNγ and IFNγ-Rα); no significant differences were found
to IFNγ-Rβ between the three sample groups (Table 1).
ELISA analysis
In the ELISA analysis, a linear correlation was found
between the optic density and the homogenized tissue
increasing concentrations (Figs. 2).
Immunohistochemistry analysis
No immunoreaction was observed in negative controls
incubated with pre-immune serum, or using the antibod-
ies pre-absorbed with excess of purified antigens. Immu-
noreaction to IFNγ and it receptor complex, always
appeared in sections of human thymus (positive controls)
for all antibodies (data not shown).
For the three proteins (IFNγ and it receptor complex), the
percentage of positive samples (positive patient) and the
optical density of immunoreaction are shown in Table 2.
In infiltrating tumor samples, imunoreactions to IFNγ,
IFNγ-Rα and IFNγ-Rβ were compared with several tumor
ELISA determinations of IFNγ and its receptors inbenign lesions, in situ carcinoma and infiltrating carcinoma Figure 2
ELISA determinations of IFNγ and its receptors inbenign lesions, in situ carcinoma and infiltrating carcinoma. Antibody binding 
was followed at 405 nm, using peroxidase-conjugated immunoglobulins. The mean values and S.D. for each group have been 
calculated from five samples corresponding to the group. O.D., optical density.BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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parameters (nodal status, TNM system and ER/PR status)
(Table 3).
IFNγ immunostaining
IFNγ was immunolocalized always in the cytoplasm of
epithelial cells. The highest percentage of positive samples
(70.6%) to IFNγ was found in the benign lesion group
(Fig. 3A), while in tumor cases the number of positive
samples was lower. The most intense immunoreaction
was found in the 35% in situ tumors (Fig. 3B). The per-
centage of positive infiltrating tumors was similar as that
found in in situ cases, but the intensity of immunoreaction
was slightly decreased (Fig. 3C).
IFNγ-Rα immunostaining
The IFNγ receptor α was localized in the epithelial cell
cytoplasm, in the three breast groups. The most of benign
lesions (88.2%) were positive to Rα (Fig. 3D). Only
41.4% of in situ tumors were positive to α-chain receptor
(Fig. 3E), but there were not significantly differences in
the intensity of immunoreaction respect to that of the
benign lesion group. A significantly decrease of immu-
noexpression and of percentage of positive samples
(28.9%) were found in infiltrating breast tumors (Fig. 3F)
in comparison with those of the other two groups (Table
2).
IFNγ-Rβ immunostaining
The three sample groups showed a similar immunoreac-
tion to IFNγ-Rβ (Table 2). The IFNγ receptor β appeared in
both cytoplasm and nuclei of epithelial cells of the three
groups studied. A 41.1% of benign lesions was immuno-
positive to β-chain, in 42.8% the cytoplasm was positive
(Fig. 3G), and 57.14% nucleus was positive (Fig. 3G
inset).
A 55.1% of in situ tumors was positive to IFNγ-Rβ and in
the most of them (93.76%) receptor β was immunolocal-
ized in the nucleus (Fig. 3H).
In infiltrating carcinomas, only 22.2% of patients were
positive to IFNγ-Rβ, but in 60% of positive samples IFNγ-
Rβ appeared in the nuclei of epithelial cells (Fig. 3I inset).
Co-localization analysis
The results obtained by immunohistochemistry were cor-
roborated by co-localization analysis (Fig. 4).
Proliferation and apoptosis analysis
The results of the immunoreaction to PCNA and TUNEL
(expressed in positive cell percentages) are shown in Table
4. In benign diseases only 3.8% cells were positive to
PCNA, while in tumor cases this percentage increased to
19% (in situ) and to 23.8% (infiltrating). The apoptosis
index was 0.19% in the benign conditions. In tumor sam-
ples the index was significantly higher; no significant dif-
ferences were found between cancer types.
Discussion
Neoplasia occurs as a result of cellular changes that per-
turb normal balances between cell growth and cell death.
These changes could be caused by an altered expression of
several factors including IFNγ. In the present study we
have found moderate expression of IFNγ (70.6% of cases)
and IFNγ-Rα (88.2% of cases) in most of benign lesions
samples. However, β subunit of this receptor appeared
only in 41.2% of cases in this group, suggesting that there




Optical density % positive 
samples
Optical density % positive samples Optical density
cytoplasm nucleus








40% 18.9 ± 2.1a 28.9% 9.9 ± 2.1b 22.2% 18.6 ± 2.9a
20% 80%
Comparison of immunostaining intensities and positive samples (obtained by inmunohistochemical analysis) between groups of breast samples. The 
labelled cells are classified in three groups according to their intensity range: low (< 10), intermediate (between 10 and 15) and high (>15). Mean ± 
SD. Values denoted by different superscripts are significantly different from each other. Those values sharing the same superscript are not 
statistically different from each other. Statistical analysis refers to each antibody separately. Significance was determined by multiple comparisons by 
the Fisher test at p ≤ 0.05.BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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was a basal activity of IFNγ in non-neoplasic tissues. The
IFNγ activity could be regulated by the expression of IFNγ-
Rβ; therefore it is necessary to constitute the functional
receptor to start the signal transduction [19]. Both IFNγ
and its receptor appeared in the epithelial cells only, indi-
cating that this cytokine acts in autocrine manner in order
to control cell proliferation. Other authors stated that, in
breast epithelial cells, the anti-proliferative effects of IFNγ
occur by up-regulation of apoptotic members of the bcl-2
family [20]. In previous studies we reported low expres-
sion of bcl-2 in benign breast disorders [21]; this agrees
with the low proliferation index and the high apoptotic
index found in this group of cases. All these data are con-
sistent with the proliferation/apoptosis equilibrium
observed in non-malignant breast tissue.
In in situ carcinomas we found an increased expression of
both IFNγ and IFNγ-Rα. However, the number of positive
patients was lower than in benign diseases. There was no
statistical difference in IFNγ-Rβ expression compared with
benign diseases, but the location of this membrane recep-
tor was in the nuclei of epithelial cells in most of in situ
tumor cases (93.7%). These findings suggest a loss of IFNγ
activity in breast epithelium in in situ tumors. Contrarily
with our results, other authors have reported nuclear accu-
mulation of IFNγ and IFNγ-Rα in the WISH cell line [22];
and, we found nuclear location only for IFNγ-Rβ. Doherty
et al. [23] have stated that the lack of endogenous IFNγ at
the tumor site, and also the inactivation of either the
receptor components or the signal transduction pathway
elements, could lead to a selective advantage for those
mutated cells. In agreement with these statements, we
have found a high proliferation index in the in situ tumor
group. This could be caused by a lack of IFNγ activity due
to the unusual location of β receptor subunit. This effect
could mean the loss of the antitumoral effects of IFNγ in
early stages of human breast cancer. Although this is the
first time that IFNγ-Rβ was found in the nucleus. So other
proteins such as p53 or p21 changed his location in breast
cancer, probably due to mutant forms of these proteins
that present different functions, as occurs in the most of
cancers, and it could be associated with the cancer devel-
opment and progression [24,25].
In prostate cancer cells it has been reported that IFNγ
apoptotic effects are promoted by p21 stimulation, which
inhibits G1 and S phase of cell cycle [26]. In breast cancer
cell lines, IFNγ treatment produces an increase in p21
[18]. Our results suggest that IFNγ could be non-func-
tional and unable to activate p21 to stop the cell cycle. In
this sense, in a previous study, we detected p21 in the
cytoplasm of epithelial cells in in situ carcinomas, and this
Table 3: Comparison of expression with clinical parameters.
Number of cases (45) IFNγ*I F N γ-Rα*I F N γ-Rβ*
Nodal status
Negative 23 7 7 5
Positive 22 11 p = 0.416 6 p = 1.000 5 p = 1,000
TNM
T 1 1 7 786
T 2 1 8 943
T 3 6111
T4 4 1 p = 0.756 0 p = 0.396 0 p = 0.543
ER
Negative 6 5 0 4
Positive 39 13 p = 0.268 13 p = 0.320 6 p = 0.071
PR
Negative 15 8 3 2
Positive 30 10 p = 0.563 10 p = 0.734 8 p = 0.706
Comparison of expression IFNγ, IFNγ-Rα and IFNγ-Rβ (only positive samples in each group were compared) with several anatomo-pathological 
features as nodal status, the TNM system and the ER/PR status in breast infiltrating carcinoma samples. *Number of positive cases
Table 4: PCNA & TUNEL.
PCNA TUNEL
Benign lesions 3.8 ± 2.5a 0.19 ± 0.02a
in situ carcinoma 19.2 ± 5.5b 1 ± 0.4b
Infiltrating carcinoma 23.8 ± 5.6c 1.5 ± 0.5b
PCNA & TUNEL analysis were measured as average optical density ± SD. Values denoted by different superscripts are significantly different from 
each other. Those values sharing the same superscript are not statistically different from each other. Statistical analysis refers to each antibody 
separately. Significance was determined by multiple comparisons by the Fisher test at p ≤ 0.05.BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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A-C. Immunostaining to IFNγ was observed always in the cytoplasm of epithelial cells Figure 3
A-C. Immunostaining to IFNγ was observed always in the cytoplasm of epithelial cells. Similar immunoreaction was found in 
benign lesion (A) and in infiltrating carcinomas (C). Cases of in situ carcinoma (B) showed the highest immunoreaction intensity. 
Bar: 20 μm (A) and 15 μm (B and C). D-F: Immunostaining to IFNγ-Rα is localized in the cytoplasm of epithelial cells in the 
three breast groups. Similar immunoreaction was found in benign lesion (D) and in in situ patients (E). The reaction intensity 
was lower in infiltrating carcinomas (F) than in the other two groups. Bar: 15 μm (D and E) and 25 μm (F). G-I: The three sam-
ple groups showed a similar immunoreaction to IFNγ-Rβ. Immunostaining is localized in both the peripheral cytoplasm (G) and 
the nucleus (inset) in benign lesion group. This immunoreaction intensity was similar to that found in the other two groups. 
Most of in situ samples (H) and infiltrating carcinoma cases (I) showed nuclear immunostainig to IFN-Rβ. Bar: 10 μm (G) and 20 
μm (H and I).BMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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suggests that the p21 cytoplasmic product does not reach
to enter the nucleus, and therefore, it would not be func-
tional and would not contribute to the cell cycle arrest
[27]. Furthermore, this p21 location has been related to
breast cancer resistance to the TNF-α apoptotic effect [28],
and it could be explained by the IFNγ effects mediated by
TNFRI [29]. According with these data, in a previous study
we described a high expression of TNFRI in in situ carcino-
mas of the breast [30]. Although IFNγ effects mediated by
TNFRI would be inhibited by the presence of p21 in the
cell cytoplasm, the p21 location in in situ carcinomas
would be capable to inhibit the apoptotic pathway of
TNFRI at ASK-1 level [31], and thus, to prevent the IFNγ
function as cell cycle inhibitor.
The group of infiltrating adenocarcinomas showed a
lower expression of IFNγ than the in situ group, and a sim-
ilar expression to that observed in the benign disease
group. However, the number of positive cases was lower
(40%) and similar to in situ carcinoma (35%). For IFNγ-
Rα, the intensity of reaction and the number of positive
cases decreased. IFNγ-Rβ showed similar reaction inten-
sity in the two carcinoma groups, and the immunoreac-
tion appeared in the cell nuclei. These data suggest a loss
of IFNγ antitumoral activity in these tumors. IFNγ, via IRF-
5 (interferon regulatory factor-5), can stimulate the expres-
sion of apoptotic genes as bax [32]. Therefore, the
decreased IFNγ positive samples could result in an altered
bax/bcl-2 balance. Ruiz-Ruiz and Lopez-Rivas [33] have
suggested that, in breast cancer cell lines, IFNγ favors acti-
vation of mitochondria-operated apoptotic pathway by
TRAIL; this activation can be inhibited in bcl-2 overex-
pressing cells. We reported an overexpression of bcl-2 in a
previous study [21] in all these tumors and in the same
A-B Inmunostainig to IFN-γ (black) and IFN-Rα (red) in benign (A) and in infiltrating cancer (B) Figure 4
A-B Inmunostainig to IFN-γ (black) and IFN-Rα (red) in benign (A) and in infiltrating cancer (B). C-D Immunostainig to IFN-γ 
(black) and IFN-Rβ (red) in in situ (C) and in infiltrating breast cancer (D). Bar: 15 μmBMC Cancer 2007, 7:158 http://www.biomedcentral.com/1471-2407/7/158
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patients used in this study; this overexpression could lead
to the inhibition of IFNγ apoptotic effects, resulting in
deregulation of the proliferation/apoptosis equilibrium
towards proliferation. This effect could be the cause of the
higher proliferation index found in these samples (up to
23% cells) respect to that observed in both benign dis-
eases and in situ tumors. Therefore, present observations
could suggest that IFNγ could be a potential therapeutic
tool in breast cancer. However, tumor cells are able to
escape from the control of this cytokine in the early tumor
stages; this could be due to a decreased expression of IFNγ,
or also to an alteration of either its receptors.
Conclusion
We conclude that the decrease in the % positive samples
that expressed IFNγ and IFNγ-Rα together with the nuclear
localization of IFNγ-Rβ, could be a tumoral cell response,
although possibly insufficient to inhibit the uncontrolled
cell proliferation. IFNγ might be unable to activate p21 to
stop the cell cycle, suggesting a possible participation in
breast cancer development.
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